JP2008528608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528608A5 JP2008528608A5 JP2007553225A JP2007553225A JP2008528608A5 JP 2008528608 A5 JP2008528608 A5 JP 2008528608A5 JP 2007553225 A JP2007553225 A JP 2007553225A JP 2007553225 A JP2007553225 A JP 2007553225A JP 2008528608 A5 JP2008528608 A5 JP 2008528608A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- immune response
- bacterial
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 230000028993 immune response Effects 0.000 claims 8
- 229930186217 Glycolipid Natural products 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 4
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims 3
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims 3
- 241000606701 Rickettsia Species 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims 3
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 | |
| US60/648,153 | 2005-01-28 | ||
| PCT/US2006/002781 WO2006083671A2 (en) | 2005-01-28 | 2006-01-26 | Bacterial glycolipid activation of cd1d-restricted nkt cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528608A JP2008528608A (ja) | 2008-07-31 |
| JP2008528608A5 true JP2008528608A5 (enExample) | 2009-03-19 |
| JP5053101B2 JP5053101B2 (ja) | 2012-10-17 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553225A Expired - Fee Related JP5053101B2 (ja) | 2005-01-28 | 2006-01-26 | ＣＤ１ｄ−拘束ＮＫＴ細胞の細菌糖脂質による活性化 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (enExample) |
| EP (1) | EP1848813B1 (enExample) |
| JP (1) | JP5053101B2 (enExample) |
| AU (1) | AU2006211485B2 (enExample) |
| BR (1) | BRPI0607299A2 (enExample) |
| CA (1) | CA2593715C (enExample) |
| DK (1) | DK1848813T3 (enExample) |
| ES (1) | ES2423005T3 (enExample) |
| PL (1) | PL1848813T3 (enExample) |
| PT (1) | PT1848813E (enExample) |
| WO (1) | WO2006083671A2 (enExample) |
| ZA (1) | ZA200706208B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| SI2056842T1 (sl) * | 2006-04-07 | 2013-02-28 | The Scripps Research Institute | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| JP2010523724A (ja) * | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| AU2013202869B2 (en) * | 2007-11-07 | 2015-10-22 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2058011A1 (en) | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| EP2231145B1 (en) | 2007-12-05 | 2014-09-17 | Wittycell | Use of glycosylceramides for enhancing the immune response to antigens |
| CN102215864A (zh) * | 2008-10-08 | 2011-10-12 | 威蒂赛尔公司 | 用于抗流感的疫苗组合物 |
| CA2753641C (en) | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| US9764037B2 (en) * | 2012-12-06 | 2017-09-19 | Victoria Link Limited | Conjugate compounds |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| EP4138849A4 (en) * | 2020-04-23 | 2024-04-17 | The Regents of the University of California | CLEARANCE OF SENESCENT CELLS BY ACTIVATION OF INKT LYMPHOCYTES |
| WO2022129549A1 (en) * | 2020-12-18 | 2022-06-23 | L'oreal | Extract of bacteria of the genus sphingomonas |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| IL305579A (en) | 2021-03-01 | 2023-10-01 | Deciduous Therapeutics Inc | Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| CA2147629C (en) | 1992-10-22 | 2005-03-22 | Koji Akimoto | Novel sphingoglycolipids and the use thereof |
| AU683653B2 (en) | 1993-04-15 | 1997-11-20 | Kirin Pharma Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| CA2162478A1 (en) | 1993-05-14 | 1994-11-24 | Shawn A. Defrees | Sialyl lex analogues as inhibitors of cellular adhesion |
| CN1222293C (zh) | 1997-04-10 | 2005-10-12 | 麒麟麦酒株式会社 | 含有α－糖基神经酰胺的NKT细胞活化剂 |
| JP2001515868A (ja) * | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Ｃｄ１制限免疫応答のための合成抗原 |
| AU2001252599A1 (en) | 2000-04-28 | 2001-11-12 | Orient Cancer Therapy Co., Ltd. | Remedies for cancer |
| US20020071842A1 (en) * | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| PT1297017E (pt) * | 2000-06-19 | 2012-09-04 | Gen Hospital Corp | Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| EP1434859A2 (en) | 2001-07-25 | 2004-07-07 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| JP2005533057A (ja) * | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| AU2003225891A1 (en) | 2003-03-20 | 2004-11-19 | Brigham Young University | 6"-amino-6"-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| US7998739B2 (en) | 2004-09-03 | 2011-08-16 | The Scipps Research Institute | Methods of activating NKT cells |
| SI2056842T1 (sl) | 2006-04-07 | 2013-02-28 | The Scripps Research Institute | Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
-
2006
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es active Active
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Not-in-force
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528608A5 (enExample) | ||
| US12264170B2 (en) | Antimicrobial organosilanes | |
| Clarke | Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands | |
| WO2006083671B1 (en) | Bacterial glycolipid activation of cd1d-restricted nkt cells | |
| WO2010006315A3 (en) | Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents | |
| CN105362212A (zh) | 一种免洗手消毒凝胶及其制备方法 | |
| NZ590472A (en) | Ophthalmic device having therapeutic agent delivery capability and method of forming same | |
| NZ591103A (en) | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | |
| RU2016109925A (ru) | Адъюванты на масляной основе | |
| JP2011525911A5 (enExample) | ||
| JP2013542992A5 (enExample) | ||
| CA3018866A1 (en) | Sanitizer composition with probiotic/prebiotic active ingredient | |
| JP2009504660A5 (enExample) | ||
| CN111454653A (zh) | 一种环保抗菌水性木器涂料及其制备方法 | |
| CA2874508C (en) | Aqueous alcoholic microbicidal compositions comprising zinc ions | |
| De Carvalho et al. | Chitosan as an oral antimicrobial agent | |
| CA2800424C (en) | B1,2 cyclic beta glucan compound for use to enhance adaptive immunity by activation of dendritic cells | |
| JP2007045732A5 (enExample) | ||
| WO2009102808A3 (en) | Doxorubicin adjuvants to reduce toxicity and methods for using the same | |
| JP2008509939A5 (enExample) | ||
| JP2013501775A5 (enExample) | ||
| PH12016501747A1 (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof | |
| JP2015528509A5 (enExample) | ||
| Inoue et al. | Antibacterial characteristics of newly developed amphiphilic lipids and DNA–lipid complexes against bacteria | |
| CN101972272B (zh) | 一种二氧化氯皮肤凝胶及其制备方法 |